Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevnar and Pneumovax in Pneumococcal Pneumonia Survivors
NCT00304382Phase 4Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2003
- Primary completion
- Sep 2006
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pneumococcal 7-valent conjugate vaccine in pneumococcal infection (4 arms), sponsored by VA Office of Research & Development. Primary endpoints: Antibody to capsular polysaccharide by ELISA at 30 days and Opsonophagocytic activity at 30 days. Started Jan 2003; status: completed.
02
Drugs
pneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00304382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304382.